Clinical Trial Detail

NCT ID NCT02349633
Title Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pfizer
Indications

lung non-small cell carcinoma

Therapies

Avelumab + Mavelertinib

Mavelertinib + Palbociclib

Mavelertinib

Age Groups: adult senior

No variant requirements are available.